Head-to-head · free

Novo Nordisk A/S vs PDS Biotechnology Corporation

NVO vs PDSB — return on capital, cash generation, margins and balance sheet side by side.

NVO

1 / 2

measures where NVO leads

PDSB

1 / 2

measures where PDSB leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureNVOPDSB · FY2025
Revenue——
Net income—(8.5M)
Revenue growth (yearly, multi-year)——
Free cash flow—(27.8M)
Free cash flow margin——
Net cash / (debt)——
ROIC34.2%—
Return on equity60.7%-244.2%
Gross margin81.0%—
Operating margin41.3%—
Net debt / EBITDA0.67x0.31x

Figures are as reported by each company; latest fiscal year shown.

Where Novo Nordisk A/S's cash went

Not reported yet.

Full NVO profile →

Where PDS Biotechnology Corporation's cash went (FY2025)

Capital spending
$0
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full PDSB profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons